Svein Lien appointed ceo of Biotec Pharmacon

Lien has a financial background and extensive experience at technology and diagnostics businesses

Svein Lien has become chief executive of Norwegian pharmaceutical firm Biotec Pharmacon following the resignation of Lars Viksmoen.

Lien has a financial background and extensive experience at technology and diagnostics businesses, most recently as chief executive of Axis-Shield, a diagnostic company listed in London and Oslo.

Following divestment of Immunocorp Animal Health in 2008 and Immunocorp Consumer Health at the end of 2009 Biotec Pharmacon has narrowed its strategic focus to two core business areas: pharmaceutical development and marine biochemicals.

Pharmaceutical development is in the research and development phase, while Biotec Marine Biochemicals specialises in cold-adapted marine enzymes for the molecular biology and diagnostics markets.

You may also like

Ingredients

ArcticZymes receives research grant of US$1.3m

To develop new enzymes for research and diagnostics
Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Sustainability

Free online course introduces fundamentals of SFC

Learn how SFC can improve efficiency and reduce environmental impact
Manufacturing

Thermo Fisher launches general purpose centrifuges with natural refrigerant cooling

New X and S Series models offer high performance with reduced environmental impact
Research & Development

€2.5m boost for SensABLATE to revolutionise real-time lung cancer treatment

The next-generation AI and photonics system is designed to provide instant intraoperative confirmation during lung cancer ablation and aims to improve precision, reduce repeat procedures and enhance patient outcomes
Pharmaceutical

Samsung Bioepis expands European biosimilar portfolio with OBODENCE and XBRYK launches

The products, targeting osteoporosis and bone-related complications in cancer, strengthen access to affordable care and expand the company’s direct sales footprint across endocrinology and oncology
Regulatory

EU approves Sanofi and Regeneron’s Dupixent as first targeted CSU treatment in more than a decade

The European Commission has authorised Dupixent for moderate-to-severe chronic spontaneous urticaria in patients aged 12+, offering the first new targeted option in more than ten years
Subscribe now